Activity and potential role of licofelone in the management of osteoarthritis

References

• AbrahamWMLauferSTriesS1997The effects of ML 3000 on antigen-induced responses in sheepPulm Pharmacol Ther10167739514627
   PubMed Web of Science ®Google Scholar
• AlgateDRAugustinJAttersonPR1995General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animalsArzneimittelforschung45159657710439
   PubMed Web of Science ®Google Scholar
• BertoliniAOttaniASandriniM2002Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarksCurr Med Chem910334312733982
   PubMed Web of Science ®Google Scholar
• BlancoFBuchnerABiasP2003Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee [abstract]Ann Rheum Dis62Suppl. 1262FRI0217.
   Google Scholar
• BuchnerABiasPLammerichA2003Twice the therapeutic dose of licofelone–an inhibitor of COX-1, COX-2 and 5-LOX–results in a significantly lower gastrointestinal ulcer incidence than naproxen in osteoarthritis patients, when administered with or without concomitant low-dose aspirinAnn Rheum Dis621 Suppl.26112594116
   PubMed Web of Science ®Google Scholar
• CelottiFLauferS2001Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition conceptPharmacol Res434293611394934
   PubMed Web of Science ®Google Scholar
• ChambersMGCoxLChongL2001Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort miceArthritis Rheum4414556511407708
   PubMed Web of Science ®Google Scholar
• FiorucciSDistruttiEDe LimaOM2003Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirinFASEB J1791171312709408
   PubMed Web of Science ®Google Scholar
• FiorucciSMeliRBucciM2001Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?Biochem Pharmacol621433811728379
   PubMed Web of Science ®Google Scholar
• GayRENeidhartMPatakyF2001Dual inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritisJ Rheumatol282060511550975
   PubMed Web of Science ®Google Scholar
• HansenESFoghKHjortdalVE1990Synovitis reduced by inhibition of leukotriene B4. Carrageenan-induced gonarthritis studied in dogsActa Orthop Scand61207122164743
   PubMed Web of Science ®Google Scholar
• HeWPelletierJPMartel-PelletierJ2002The synthesis of interleukin-1beta, tumour necrosis factor-a and interstitial collagenase (MMP-1) is eicosanoid dependent in human OA synovial membrane explants: Interactions with anti-inflammatory cytokinesJ Rheumatol295465311908571
   PubMed Web of Science ®Google Scholar
• HeidemannATriesSLauferS1995Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acidArzneimittelforschung45486907779147
   PubMed Web of Science ®Google Scholar
• HuskissonECBerryHGishenP1995Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal antiinflammatory drugs in knee osteoarthritisJ Rheumatol22194168991995
   PubMed Web of Science ®Google Scholar
• JovanovicDVFernandesJCMartel-PelletierJ2001In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesisArthritis Rheum4423203011665972
   PubMed Web of Science ®Google Scholar
• KlesserBBiasPBuchnerA2002Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatmentAnn Rheum Dis61Suppl. 1121211796397
   PubMed Web of Science ®Google Scholar
• KonttinenYTMandelinJLiTF2002Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritisArthritis Rheum469536011953972
   PubMed Web of Science ®Google Scholar
• LarkMWBayneEKFlanaganJ1997Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid jointsJ Clin Invest100931069202061
   PubMed Web of Science ®Google Scholar
• LauferSTriesSAugustinJ1995Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acidArzneimittelforschung4527327893265
   PubMed Web of Science ®Google Scholar
• LauferSTriesSAugustinJ1994Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenaseArzneimittelforschung44629368024637
   PubMed Web of Science ®Google Scholar
• LevalXJulemontFDelargeJ2002New trends in dual 5-LOX/COX inhibitionCurr Med Chem99416211966455
   PubMed Web of Science ®Google Scholar
• MarcouillerPPelletierJPGuévremontM2005Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for IL-1beta synthesisJ Rheumatol327041215801029
   PubMed Web of Science ®Google Scholar
• Martel-PelletierJLajeunesseDPelletierJP2004Etiopathogenesis of osteoarthritis. In: Koopman WJ (ed). Arthritis and allied conditions. A textbook of rheumatologyBaltimore: Lippincott, Williams & Wilkins2199226
   Google Scholar
• Martel-PelletierJLajeunesseDReboulP2003Therapeutic role of dual inhibitors of 5-LOX and COX, selective and nonselective non-steroidal anti-inflammatory drugsAnn Rheum Dis62501912759283
   PubMed Web of Science ®Google Scholar
• Martel-PelletierJWelschDJPelletierJP2001Metalloproteases and inhibitors in arthritic diseasesWoolfADBaillière’s best practice and research clinical rheumatologyEast Sussex, UKBaillière Tindall80529
   Google Scholar
• MoreauMBoileauCMartel-PelletierJ2006Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activityJ Rheumatol3311768316652435
   PubMed Web of Science ®Google Scholar
• NagaseHKashiwagiM2003Aggrecanases and cartilage matrix degradationArthritis Res Ther59410312718749
   PubMed Web of Science ®Google Scholar
• PalmoskiMJBrandtKD1983In vivo effect of aspirin on canine osteo-arthritic cartilageArthritis Rheum2699410016882492
   PubMed Web of Science ®Google Scholar
• ParadesYMassicotteFPelletierJP2002Study of the role of leu-kotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibitionArthritis Rheum4618041212124864
   PubMed Web of Science ®Google Scholar
• ParenteL2001Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better then one?J Rheumatol28237538211708405
   PubMed Web of Science ®Google Scholar
• PavelkaKBiasPBuchnerA2003Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the kneeAnn Rheum Dis62Suppl. 126112594116
   PubMed Web of Science ®Google Scholar
• PelletierJPDi BattistaJARaynoudJP1995The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1 and oncogene protein synthesis in experimental osteoarthritisLab Invest72578867745952
   PubMed Web of Science ®Google Scholar
• PelletierJPLajennesseDJovanovicDV2000Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritisJ Rheumatol27289390211128682
   PubMed Web of Science ®Google Scholar
• PelletierJPMartel-PelletierJAbramsonSB2001Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targetsArthritis Rheum4412374711407681
   PubMed Web of Science ®Google Scholar
• PelletierJPMartel-PelletierJ1991In vivo protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog modelJ Rheumatol2712730
   Google Scholar
• PretePEGurakar-OsborneA1997The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritisProstaglandins54689989440132
   PubMed Web of Science ®Google Scholar
• RainsfordKDYingCSmithF1996Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture; comparison with interleukin-1-synthesis inhibitorsJ Pharm Pharmacol4846528722494
   PubMed Web of Science ®Google Scholar
• RainsfordKDYingCSmithF1996Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitorsJ Pharm Pharmacol4846528722494
   PubMed Web of Science ®Google Scholar
• ReginsterJYBiasPBuchnerA2002First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarhtritisAnn Rheum Dis61Suppl. 111617
   Google Scholar
• RotondoSDell’ElbaGKrauze BrzoskoK2002Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and plateletEur J Pharmacol453131912393068
   PubMed Web of Science ®Google Scholar
• RotondoSKrauze BrzoskoKManariniS2004Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activationEur J Pharmacol488798315044038
   PubMed Web of Science ®Google Scholar
• SerhanCN2001Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counter-regulatory sideArch Immunol Ther Exp4917788
   PubMed Web of Science ®Google Scholar
• SinghVPPatilCSKulkarniSK2006Anti-inflammatory effect of licofelone against various inflammatory challengesFundam Clin Pharmacol20657116448396
   PubMed Web of Science ®Google Scholar
• SipeJDBartleLMLooseLD1992Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase responseJ Immunol14848041729367
   PubMed Web of Science ®Google Scholar
• SkellyMMHawkeyCJ2003COX–LOX inhibition: current evidence for an emerging new therapyInt J Clin Pract57301412800462
   PubMed Web of Science ®Google Scholar
• WallaceJLCarterLMcKnightW1994ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injuryEur J Pharmacol271525317705453
   PubMed Web of Science ®Google Scholar
• WolfeFAndersonJBurkeTA2002Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapyJ Rheumatol294677311908558
   PubMed Web of Science ®Google Scholar